<code id='7C99E3A0E7'></code><style id='7C99E3A0E7'></style>
    • <acronym id='7C99E3A0E7'></acronym>
      <center id='7C99E3A0E7'><center id='7C99E3A0E7'><tfoot id='7C99E3A0E7'></tfoot></center><abbr id='7C99E3A0E7'><dir id='7C99E3A0E7'><tfoot id='7C99E3A0E7'></tfoot><noframes id='7C99E3A0E7'>

    • <optgroup id='7C99E3A0E7'><strike id='7C99E3A0E7'><sup id='7C99E3A0E7'></sup></strike><code id='7C99E3A0E7'></code></optgroup>
        1. <b id='7C99E3A0E7'><label id='7C99E3A0E7'><select id='7C99E3A0E7'><dt id='7C99E3A0E7'><span id='7C99E3A0E7'></span></dt></select></label></b><u id='7C99E3A0E7'></u>
          <i id='7C99E3A0E7'><strike id='7C99E3A0E7'><tt id='7C99E3A0E7'><pre id='7C99E3A0E7'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:focus    Page View:34
          Portrait of Robert Langer. -- biotech coverage from STAT.
          Serial biotech entrepreneur Bob Langer will serve as an adviser to T.rx Capital. Pat Greenhouse/Globe Staff

          Executives from the shuttered digital health company Pear Therapeutics are launching a new VC firm, offering early access to new startups formed by serial biotech entrepreneur Bob Langer.

          Former Pear CEO Corey McCann and former licensing head Michael Langer formed the new firm, T.rx Capital, earlier this year, according to three people with knowledge of the firm and documents reviewed by STAT. Michael Langer, the son of Bob Langer, confirmed the news and that they had set a $175 million cap for its first fund.

          advertisement

          The firm will invest in therapeutics and digital health products by both forming new companies and taking pitches from early-stage startups. T.rx has brought in Everly Health executive Liz Kwo and Caris Life Sciences vice president Debbie Lin as venture partners, while current Eli Lilly business development team member Kwesi Frimpong-Boateng will be joining T.rx’s founding team. Bob Langer is a scientific adviser.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          Shionogi licenses Pompe disease therapy from Maze Therapeutics
          Shionogi licenses Pompe disease therapy from Maze Therapeutics

          MazeTherapeuticsCEOJasonColomaCourtesyAfterseeingitslastdealgobustinthefaceofregulatoryscrutiny,Maze

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          FDA approves RSV monoclonal antibody for infants, toddlers

          SanofiTheFoodandDrugAdministrationapprovedamonoclonalantibodytoprotectinfantsandyoungchildrenfromsev